TABLE 2.
Effects of ABC294640 on tumor cell proliferation
Sparsely plated cells were treated with ABC294640 for 48 h, and the number of viable cells was determined and compared with vehicle (DMSO)-treated cells as described in Materials and Methods. Values are the mean ± S.E.M. for at least three separate experiments.
| Cell Line | Tissue | IC50 | Cell Line | Tissue | IC50 |
|---|---|---|---|---|---|
| μM | μM | ||||
| 1025LU | Melanoma | 33.7 ± 2.7 | Hep-G2 | Liver | 6.0 ± 2.6 |
| A-498 | Kidney | 12.2 ± 6.0 | MCF-7 | Breast, ER+ | 18.4 ± 7.4 |
| Caco-2 | Colon | 11.8 ± 5.6 | MDA-MB-231 | Breast, ER− | 29.1 ± 11.1 |
| HT-29 | Colon | 48.1 ± 7.6 | Panc-1 | Pancreas | 32.8 ± 0.1 |
| DU145 | Prostate | 21.9 ± 1.5 | T24 | Bladder | 39.4 ± 7.4 |
| SK-OV-3 | Ovary | 10.5 ± 2.6 |
ER+, estrogen receptor positive; ER−, estrogen receptor negative.